title: Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages.
abstract: The emphysema of alpha 1-antitrypsin (alpha 1AT) deficiency is conceptualized to result from insufficient alpha 1AT allowing neutrophil elastase to destroy lung parenchyma. In addition to the deficiency of alpha 1AT in these individuals resulting from mutations in the alpha 1AT gene, it is recognized that, for unknown reasons, there are also increased numbers of neutrophils in their lungs compared with normal individuals. With the knowledge that alveolar macrophages have surface receptors for neutrophil elastase, we hypothesized that the neutrophil accumulation in the lower respiratory tract in alpha 1AT deficiency may result, in part, from release of neutrophil chemotactic activity by alveolar macrophages as they bind uninhibited neutrophil elastase. Consistent with this hypothesis, alpha 1AT-deficient alveolar macrophages spontaneously released nearly threefold more neutrophil chemotactic activity than normal alveolar macrophages. Analysis of alpha 1AT-deficient macrophage supernates by reverse-phase HPLC, molecular sieve chromatography, radioimmunoassay, and absorption with anti-LTB4 antibody revealed that the majority of the chemotactic activity was leukotriene B4 (LTB4), a mediator absent from normal macrophage supernates. Consistent with this hypothesis, incubation of normal macrophages with human neutrophil elastase resulted in the release of the same neutrophil chemotactic mediator. Furthermore, purified human alpha 1AT was able to prevent the neutrophil elastase from stimulating the macrophages to release the chemotactic factor. Together, these findings suggest that the absence of a normal antineutrophil elastase screen in the lower respiratory tract permits free neutrophil elastase to bind to alveolar macrophages, resulting in the release of LTB4, a process which attracts neutrophils to the alveoli of alpha 1AT deficient individuals, thus accelerating the lung destruction that characterizes this disorder.
authors.affiliation: Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892.
authors.forename: R C
authors.initials: RC
authors.lastname: Hubbard
authors.forename: G
authors.initials: G
authors.lastname: Fells
authors.forename: J
authors.initials: J
authors.lastname: Gadek
authors.forename: S
authors.initials: S
authors.lastname: Pacholok
authors.forename: J
authors.initials: J
authors.lastname: Humes
authors.forename: R G
authors.initials: RG
authors.lastname: Crystal
mesh_terms: D000328:Adult; D002630:Chemotactic Factors / Q000378:metabolism; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D019272:Leukocyte Elastase; D007975:Leukotriene B4 / Q000032:analysis / Q000378:metabolism*; D008168:Lung / Q000473:pathology*; D008264:Macrophages / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000276:immunology*; D010196:Pancreatic Elastase / Q000494:pharmacology; D011650:Pulmonary Alveoli / Q000378:metabolism*; D019896:alpha 1-Antitrypsin Deficiency
chemical_list: D002630:Chemotactic Factors; D007975:Leukotriene B4; D010196:Pancreatic Elastase; D019272:Leukocyte Elastase